Literature DB >> 9625440

Therapeutic effects of 5-fluorouracil microspheres on peritoneal carcinomatosis induced by Colon 26 or B-16 melanoma in mice.

A Hagiwara1, C Sakakura, M Shirasu, J Yamasaki, T Togawa, T Takahashi, S Muranishi, S Hyon, Y Ikada.   

Abstract

The delivery formulation 5-FU-MS [5-fluorouracil (5-FU) incorporated in microspheres composed of a poly(glycolide-co-lactide) matrix] slowly releases 5-FU over 3 weeks. 5-FU-MS delivers higher concentrations of the drug to the i.p. tissues for a longer period of time with lower blood plasma concentrations than does an aqueous 5-FU solution and reduces toxicity. In this study, we evaluated the therapeutic effects of 5-FU-MS on peritoneal carcinomatosis in mice. Four days after an i.p. inoculation with Colon 26 or B-16 PC melanoma, 5-FU at 200 mg/kg was administered i.p. as 5-FU-MS or as an aqueous solution of 5-FU. 5-FU-MS extended the survival of mice bearing Colon 26 or B-16 PC melanoma significantly better than the equivalent dose of aqueous 5-FU solution.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9625440     DOI: 10.1097/00001813-199803000-00012

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  2 in total

1.  Anti-hepatocarcinoma effects of 5-fluorouracil encapsulated by galactosylceramide liposomes in vivo and in vitro.

Authors:  Yong Jin; Jun Li; Long-Fu Rong; Yuan-Hai Li; Lin Guo; Shu-Yun Xu
Journal:  World J Gastroenterol       Date:  2005-05-07       Impact factor: 5.742

2.  Establishment of patient-derived xenograft model of peritoneal mucinous carcinomatosis with signet ring cells and in vivo study on the efficacy and toxicity of intraperitoneal injection of 5-fluorouracil.

Authors:  Yu-Lin Lin; Jue Zhang; Feng-Cai Yan; Xi Jiang; Ru Ma; Zhi-Ran Yang; Hong-Bin Xu; Zheng Peng; Qian Chen; Yan Li
Journal:  Cancer Med       Date:  2019-12-08       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.